High-grade Gliomas Clinical Trial
Official title:
Clinical Study of Apatinib Combined With Temozolomide in the Treatment of Uncontrolled or Repeated High-grade Gliomas
Gliomas are the most common malignant tumors of the central nervous system and are highly invasive. Gliomas account for one-third of central nervous system tumors in adults and children. Interstitial astrocytomas and glioblastomas are also called high-grade gliomas, accounting for 77.5% of all gliomas.
Temozolomide combined with concurrent radiotherapy, followed by 6 cycles of temozolomide
adjuvant chemotherapy, can prolong the patient's survival, and the 2-year survival rate has
increased from 10.4% to 26.5%. Great progress has been made, but the prognosis for glioma
patients remains poor. For patients with poor-quality high-grade gliomas, more effective new
treatments are urgently needed to achieve the purpose of survival benefit.
Targeting VEGFs to inhibit tumor angiogenesis has shown good efficacy in a variety of tumors
including colon cancer, gastric cancer, lung cancer, liver cancer and breast cancer. However,
for gliomas, anti-tumor angiogenesis drugs can improve patient OS Evidence related to PFS is
still scarce. Compared with other targeted drugs with multiple kinase targets, apatinib has
not only an advantage in price but also less side effects. Therefore, based on relevant data
from previous studies, a basic and clinical study of this apatinib combined with temozolomide
for high-grade gliomas was performed.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Terminated |
NCT00393094 -
Bevacizumab and Irinotecan to Treat Brain Tumors
|
Phase 2 | |
| Completed |
NCT02263105 -
Efficacy and Tolerability of Cisplatin Plus Alternating Weekly Temozolomide in Recurrent High-grade Gliomas
|
Phase 2 | |
| Recruiting |
NCT03904628 -
Phase I Clinical Study of Oral TG02 Capsule in the Treatment of Recurrent / Progressive High-grade Glioma Patients
|
Phase 1 |